ArticleJournal of cardiovascular medicine (Hagerstown, Md.)2026
A hemodynamic and biomarker study of pulmonary hypertension associated with heart failure: DISCOVER PH-HF.
Article in Journal of cardiovascular medicine (Hagerstown, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe pathogenesis of pulmonary hypertension associated with heart failure (PH-HF) is partially understood. To advance knowledge in this regard, the investigator-initiated, public-funded, prospective, translational stuDy to dISseCt remOdeling of capillaries and Veins in pulmonary hypErtension associated with heaRt failure (DISCOVER PH-HF) will assess biomarkers of PH-HF in pulmonary capillary and venous (PCV) and peripheral venous blood taken during right heart catheterization (RHC). This report presents the design of DISCOVER PH-HF and the baseline characteristics of the included patients.
methodsDISCOVER PH-HF enrolled heart failure patients scheduled for transcatheter edge-to-edge repair (TEER) of severe mitral regurgitation. PCV and peripheral venous whole blood was collected during RHC within 48 h before mitral regurgitation (MR)-TEER, and processed into plasma/serum aliquots and peripheral blood mononuclear cell (PBMC) pellets. Then, the samples were centralized to a core biobank. Follow-up entails visits at 90 ± 10 and 180 ± 10 days and - optionally - a second RHC with collection of PCV and peripheral venous blood within 30 days from the second follow-up evaluation. A proteomic analysis of part of the PCV and peripheral plasma is already planned.
resultsSeven patients without pulmonary hypertension at RHC, 12 patients with isolated postcapillary pulmonary hypertension, and 18 patients with combined postcapillary and precapillary pulmonary hypertension were recruited, leading to a total of 148 PCV and 148 peripheral plasma aliquots, 111 PCV and 111 peripheral serum aliquots, and 37 PBMC pellets.
conclusionDISCOVER PH-HF has generated a limited-size, but unique biobank of RHC-derived PCV and peripheral venous blood samples and PBMCs, linked to clinical and hemodynamic phenotyping, which will allow the exploration of biomarkers of PH-HF and its subtypes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.